Apollomics Inc. (APLM)
NasdaqCM: APLM
· Real-Time Price · USD
17.82
-0.34 (-1.87%)
At close: Aug 12, 2026, 10:02 AM
Apollomics Inc. (APLM) Stock Price, Analysis & Data
-1.87% (1D)
| Bid | 17.6 |
| Market Cap | 39.13M |
| Revenue (ttm) | 8.84M |
| Net Income (ttm) | -10.94M |
| Beta | 1.45 |
| EPS (ttm) | -7.57 |
| PE Ratio (ttm) | n/a |
| Forward PE | -27.42 |
| P/B (ttm) | -12.00 |
| P/S (ttm) | 4.43 |
| Earnings Date | n/a |
| Ask | 18.46 |
| Volume | 2,428 |
| Avg. Volume (20D) | 24,170 |
| Open | 17.82 |
| Previous Close | 18.16 |
| Day's Range | 17.82 - 17.82 |
| 52-Week Range | 3.66 - 42.12 |
| Analyst | n/a |
| Price Target | n/a |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About APLM
Apollomics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of oncology therapies to harness the immune system and target specific molecular pathways to inhibit cancer. The company's products portfolio includes Vebreltinib (APL-101), an oral active, highly selective c-Met inhibitor, which is in Phase 2 clinical trials for treatment of non-small cell lung cancer and other solid tumors with MET dysregulati...
Industry Biotechnology
Sector Healthcare
IPO Date Nov 26, 2021
Employees 14
Stock Exchange NasdaqCM
Ticker Symbol APLM
Website https://www.apollomicsinc.com
Financial Performance
In 2025, Apollomics's revenue was 8.5M, an increase of undefined% compared to the previous year's 0. Earnings were -10.94M, a decrease of -79.69%.
Financial Statements